---
title: "Weekly Recap | IBB.US +1.42%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298106065.md"
description: "IBB added 1.42% this week to close at $211.92, outpacing the S&P 500 by roughly 1.33 percentage points after the benchmark rose only 0.09%. The ETF opened soft on Monday, touched a weekly low of $206.01, then pushed higher to $215.31 on Wednesday before easing into Friday. The week’s range came to 4.49%."
datetime: "2026-09-05T09:03:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298106065.md)
  - [en](https://longbridge.com/en/news/298106065.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298106065.md)
generator: "portal-rs"
---

# Weekly Recap | IBB.US +1.42%, most brokers rate it buy

## The Week

IBB added 1.42% this week to close at $211.92, outpacing the S&P 500 by roughly 1.33 percentage points after the benchmark rose only 0.09%. The ETF opened soft on Monday, touched a weekly low of $206.01, then pushed higher to $215.31 on Wednesday before easing into Friday. The week’s range came to 4.49%.

## Sector News

The week’s headline flow centred on regulatory approvals and clinical data. Gilead won FDA approval for a new single-tablet HIV regimen, Biogen and Eisai announced China approval for subcutaneous LEQEMBI in early Alzheimer’s disease, and Ionis received approval for a rare neurology drug, while Pfizer struck an ADC deal. On the other flank, UK regulators suspended Amgen’s Tavneos for new patients over data reliability concerns. As a sector ETF, IBB’s weekly move largely reflected the combined weight of these names.

## The Week Ahead

On the macro side, the 10 September prints for US initial jobless claims, final-demand PPI and the 10-year Treasury auction will set the tone for risk appetite across biotech. On the sector side, the market will be watching follow-through from this week’s approvals and clinical readouts, as well as any further UK regulatory action on Tavneos.

## In Short

IBB outperformed the market this week and held above its 20-day moving average, with the latest PB around 1.73x. Sector news leaned positive, but valuations remain rich at roughly 33.6x earnings. Combined with a split in latest-session money flows, the near-term picture hinges on macro rate expectations and how the recent regulatory stories evolve.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BIS.US](https://longbridge.com/en/quote/BIS.US.md)

## Related News & Research

- [Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC](https://longbridge.com/en/news/298830378.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)
- [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md)
- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**